Gilead gets FDA breakthrough therapy status for magrolimab in MDS

This article was originally published here

Magrolimab is an investigational monoclonal antibody, which has been developed to act against CD47 and macrophage checkpoint inhibitor. It is being developed in various hematologic and solid tumour

The post Gilead gets FDA breakthrough therapy status for magrolimab in MDS appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply